Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer - Related Studies

Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer

This study is currently recruiting participants.

Study NCT00691730. Last updated on August 6, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Interventions listed in this trial
		aflibercept
		bevacizumab
		cediranib
		sunitinib malate
		immunoenzyme technique
		laboratory biomarker analysis
		pharmacological study

2	Additional drug interventions recognized in this trial
		Sunitinib

3	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

4	Sponsors listed in this trial
		Princess Margaret Hospital, Canada
		National Cancer Institute (NCI)